Clinical trials: B-Cell Non-Hodgkin Lymphoma
Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma
This phase II trial is studying how well sunitinib works in treating patients with relapsed or refractory diffuse or mediastinal large B-cell lymphoma.
- Conditions
- Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00392496
- Testing
- sunitinib malate
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Large B-Cell, Diffuse, Fatigue
Fatigue Reduction Diet in Lymphoma Survivors
The purpose of this small preliminary study is to gather preliminary data to support a large randomized controlled trial of a fatigue reduction diet intervention among diffuse-large B-cell lymphoma (DLBCL) survivors.
- Trial name
- NCT05327725
- Testing
- Fatigue Reduction Diet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lymphoma, B-Cell
External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma
The purpose of the research study is to learn whether external beam radiation can be used as a safe and effective treatment for patients with bulky (≥ 5cm) sites of non-Hodgkin's lymphoma prior to treatment with 90Y-ibritumomab…
- Trial name
- NCT00271050
- Testing
- external beam radiotherapy plus 90-Y ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Cleveland Clinic
Acute Lymphoblastic Leukemia
CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)
The aim of this clinical trial is to evaluate the feasibility, safety and biological effect of adoptive transfer of CD19ζ chimaeric receptor transduced donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTL) in patients with…
- Trial name
- CD19TPALL (NCT01195480)
- Testing
- donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta, Irradiated donor-derived Lymphoblastoid Cell Line
- Where
- 7 sites in Germany, United Kingdom
- Volunteers
- 29 people
- Sponsor
- University College, London
Leukemia, Lymphoma
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn if adding Zevalin (ibritumomab tiuxetan) to low-intensity chemotherapy (the combination of rituximab, bendamustine, and fludarabine), followed by an allogeneic stem cell…
- Trial name
- NCT01490723
- Testing
- Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic disease.
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Burkitt Lymphoma
- Trial name
- NCT00719888
- Testing
- Cyclophosphamide, Cyclosporine, Double-Unit Umbilical Cord Blood Transplantation
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00392990
- Testing
- Regimen A, Regimen B
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Lymphoma, Hodgkin Lymphoma
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Lymphoma is a prevalent lymphoid malignancy globally and in Taiwan. Large B-cell lymphoma (LBCL) is the most common subtype of aggressive B-cell lymphoma.
- Conditions
- Lymphoma, Hodgkin Lymphoma, T-cell Lymphoma, Waldenstrom Macroglobulinaemia
- Trial name
- NCT06550427
- Testing
- ctDNA analyzed by phased variant
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
NSCLC, SCLC
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research.
- Conditions
- NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT06534762
- Testing
- Mirabegron
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Zhejiang Provincial People's Hospital
Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
This study is to improve the first-line induction chemotherapy, by combining either Ibrutinib, or Lenalidomide, to a conventional immuno- chemotherapy of R-MPV type (Rituximab-Methotrexate-Procarbazine-Vincristine).
- Trial name
- LOC-R01 (NCT04446962)
- Testing
- Lenalidomide, Ibrutinib
- Where
- 28 sites in France
- Volunteers
- 118 people
- Sponsor
- Institut Curie
Lymphoma, Large-Cell, Diffuse
ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma
The primary objective of the study is to evaluate the efficacy of ASCT as consolidation in case of bcl-2 overexpression in non previously treated patients aged 60 years or less with low-intermediate risk diffuse large B-cell…
- Trial name
- NCT00169130
- Testing
- doxorubicin, cyclophosphamide, Autologous stem cell transplantation
- Where
- 5 sites in Belgium, France
- Volunteers
- 300 people
- Sponsor
- Lymphoma Study Association
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients
This is a prospective, single-arm, multi-center, phase Ib/II clinical trial to evaluate the safety, tolerability, and efficacy of selinexor in combination with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and…
- Trial name
- NCT05577364
- Testing
- Selinexor, R-CHOP Protocol
- Where
- 2 sites in China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Chidamide, R-CHOP Chemotherapy
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes
- Conditions
- Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, Double-expressor Lymphoma (DEL)
- Trial name
- NCT06891157
- Testing
- Chidamide plus R-CHOP
- Where
- China
- Volunteers
- 148 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Lymphoma, B-Cell
Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma
Chimeric antigen receptor (CAR) T cells targeting CD20 will be evaluated for safety and efficacy in patients with CD20+ B cell lymphoma.
- Trial name
- NCT02965157
- Testing
- CART20
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Biohealthcare Biotechnology Co.,Ltd
Diffuse Large B-cell Lymphoma
A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)
The main objective of the trial is to assess the efficacy and tolerability of Lonca-R in unfit and frail participants with previously untreated DLBCL.
- Trial name
- LOTIS-9 (NCT05144009)
- Testing
- Loncastuximab Tesirine, Rituximab
- Where
- 41 sites in United States, Italy and 2 more
- Volunteers
- 41 people
- Sponsor
- ADC Therapeutics S.A.
Lymphoma
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
The researchers are doing this study to find out whether the combination of epcoritamab with tafasitamab and lenalidomide is a safe and effective treatment for relapsed or refractory DLBCL.
- Trial name
- ECLAT (NCT07030699)
- Testing
- Epcoritamab, Lenalidomide, Tafasitamab
- Sponsor
- Memorial Sloan Kettering Cancer Center
DLBCL, Lymphoma, B-Cell
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
- Trial name
- NCT04594798
- Testing
- Polatuzumab vedotin, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Rochester
Lymphoma, Lymphoma, Large B-Cell, Diffuse
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma.
- Trial name
- NCT05800366
- Testing
- Glofitamab, Polatuzumab, Rituximab
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Jennifer Crombie, MD
DLBCL - Diffuse Large B Cell Lymphoma
AZA Combined with R-GemOx for Elderly DLBCL Patients
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of AZA（azacytidine）combined with the R-GemOx (rituximab, gemcitabine and oxaliplatin) regimen as first-line treatment in…
- Trial name
- Dragon (NCT06778902)
- Testing
- azacytidine, R-GemOx
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University